Icodextrin (peritoneal ultrafiltration) · Extraneal

Other

Approvedregulatory verdict

Evidence outlook

Approved: a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory... (FDA)

This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Weak signal

Also approved (3)
US
  • EXTRANEAL (icodextrin) is indicated for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy. EXTRANEAL is also indicated to improve (compared to 4.25% dextrose) long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high average or greater transport characteristics, as defined using the peritoneal equilibration test (PET); for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of kidney failure in patients requiring long-term kidney replacement therapy; to improve (compared to 4.25% dextrose) long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high average or greater transport characteristics, as defined using the peritoneal equilibration test (PET).
Product first approved 2002Outside this platform's coverageFDA label
JP
  • Continuous ambulatory peritoneal dialysis (CAPD) solution using icodextrin as the osmotic agent (Extraneal, Baxter)
Product first approved 2003Outside this platform's coveragepj.jiho.jp
CA
  • EXTRANEAL (icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride) is indicated for use as an osmotic agent for long dwell, up to 12 hours, in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD), where it can be used for 14 and up to 16 hours.
Product first approved 1999Outside this platform's coverageHealth Canada
Featured evidence outside this drug's tracked markets:EDEN (NCT01219959) · End Stage Renal Disease (ESRD), Diabetes, CAPD · Phase 3 · met primary endpoint · Partial signal

Regimen result: the experimental arm used three solutions (Dianeal, Extraneal and Nutrineal) against Dianeal only, so the effect cannot be credited to icodextrin alone.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (3)
Heart Failure
NCT01124227 · Martini Hospital Groningen
2010-04 – 2017-09 · Congestive Heart Failure
What this study did
Other / comorbidity
NCT01219959 · Vantive Health LLC
2010-10 – 2011-07 · End Stage Renal Disease (ESRD), Diabetes, CAPD
What this study did
NCT00567398 · Vantive Health LLC
2008-04 – 2011-07 · ESRD, Diabetes
What this study did
Phase 2 (2)
Heart Failure
Other / comorbidity
NCT00369096 · Fundación Renal Iñigo Alvarez De Toledo
2006-09 – 2009-05 · Peritoneal Diseases
What this study did
Phase 1 (2)
Other / comorbidity
NCT05780086 · Instituto Mexicano del Seguro Social
2023-02-03 – 2023-12-30 · Chronic Kidney Diseases
What this study did
NCT05185999 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2022-10-17 – 2023-10-20 · Chronic Kidney Failure
What this study did
Phase 4 (10)
Other / comorbidity
NCT05721404 · First Affiliated Hospital, Sun Yat-Sen University
2023-05-24 – 2027-12-31 · Peritoneal Dialysis
What this study did
NCT05943470 · RenJi Hospital
2023-08-01 – 2024-12-28 · Peritoneal Dialysis Solution Adverse Reaction
What this study did
NCT01944852 · Pr Eric Goffin
2013-03 – 2020-02-28 · Renal Insufficiency
What this study did
NCT01228279 · Ottawa Hospital Research Institute
2007-07 – 2018-12 · End-stage Renal Disease (ESRD), Kidney Disease
What this study did
NCT01044446 · Chinese University of Hong Kong
2010-01 – 2013-04 · Peritonitis
What this study did
NCT01021878 · Pontifícia Universidade Católica do Paraná
2009-10 – 2012-02 · Disorders Associated With Peritoneal Dialysis
What this study did
NCT01093547 · Vantive Health LLC
2010-02 – 2011-12 · End Stage Renal Disease, Continuous Ambulatory Peritoneal Dialysis
What this study did
NCT00567489 · Vantive Health LLC
2008-01 – 2011-07 · ESRD, Diabetes, CAPD, APD
What this study did
NCT00397358 · Vantive Health LLC
2006-11 – 2007-06 · Peritoneal Dialysis, Hypertriglyceridemia
What this study did
NCT00725517 · Shanghai Jiao Tong University School of Medicine
2005-12 – 2007-02 · Chronic Kidney Disease, Peritoneal Dialysis
What this study did
Early phase / not applicable (8)
Other / comorbidity
NCT07168343 · National University Health System, Singapore
2026-02-28 – 2028-06-30 · Children on Chronic Peritoneal Dialysis
What this study did
NCT06119373 · RenJi Hospital
2023-12-01 – 2026-11-30 · Peritoneal Dialysis Complication, Residual Kidney Function, Survival, Health-related Quality of Life
What this study did
NCT06552546 · Peking University First Hospital
2024-08-15 – 2025-03-30 · Peritoneal Dialysis
What this study did
NCT02318888 · Uppsala University
2009-12 – 2022-12 · Surgical Adhesions
What this study did
NCT02166359 · Dong-A University
2014-06 – 2019-04 · End Stage Renal Disease
What this study did
NCT01119196 · Vanderbilt University
2010-09 – 2015-01 · End Stage Renal Disease
What this study did
NCT01170858 · Yonsei University
2010-08 – 2014-08 · End Stage Renal Disease
What this study did
NCT00119990 · University of Aarhus
2006-01 – 2010-01 · Peritoneal Dialysis
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (2)
Other / comorbidity
NCT04086212 · Iperboreal Pharma Srl
2019-10-02 – 2023-04 · End Stage Renal Disease (ESRD)
What this study did
NCT01242904 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2010-09-30 – 2015-02-28 · End Stage Renal Disease
What this study did
Phase 1 (1)
Other / comorbidity
NCT00597662 · University Hospital Tuebingen
2008-01 – 2008-04 · Adhesions
What this study did

Competitive landscape

Other Peritoneal ultrafiltration drugs

PolyCore. Compare all 2 Peritoneal ultrafiltration drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Heart Failure: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Icodextrin (peritoneal Ultrafiltration) (Extraneal): this drugPhase 3Glucose Polymer Solution (peritoneal Dialysis)Peritoneal ultrafiltrationWeak signal
NCT00368641: All-cause Hospitalization (Unadjusted) (6 to 24 months): Intervention Group 5.33 hospitalizations per year (95% CI 3.13 to 9.05) vs Standard Therapy 1.69 hospitalizations per year (95% CI 0.95 to 2.99)
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Reliable signal
NCT04564742: Primary hierarchical composite outcome (win ratio analysis, DAPA-MI): win ratio 1.34 (95% CI 1.20-1.50), P<0.001, favoring dapagliflozin over placebo; n=4017 (2019 dapagliflozin vs 1998 placebo)
NCT03619213: Primary composite outcome (worsening heart failure or cardiovascular death): dapagliflozin 16.4% vs placebo 19.5%; hazard ratio 0.82 (95% CI 0.73-0.92, p<0.001)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT03057951: Primary composite endpoint (CV death or HF hospitalization) event rate: 13.8% (empagliflozin) vs 17.1% (placebo); HR 0.79, 95% CI 0.69-0.90; 21% relative risk reduction.
NCT03057977: Primary composite outcome (cardiovascular death or hospitalization for worsening heart failure) at median 16 months: 19.4% (361/1863) with empagliflozin vs 24.7% (462/1867) with placebo; hazard ratio 0.75 (95% CI 0.65-0.86), P<0.001
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT03037931: Primary endpoint, hierarchical composite of death and heart failure hospitalization at 12 months and change in 6-minute walk distance at 6 months (significance level 0.01): unmatched win ratio 1.10 (99% CI 0.99 to 1.23), Wilcoxon-Mann-Whitney P=0.02. Components, ferric carboxymaltose vs placebo: deaths 131 (8.6%) vs 158 (10.3%); heart failure hospitalizations 297 vs 332; 6-minute walk change +8 vs +4 m. missed
Finerenone (Kerendia)ApprovedSmall moleculeMineralocorticoid receptorReliable signal
NCT04435626: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months): Finerenone (BAY94-8862) 1083 events | Placebo 1283 events
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2Weak signalFeatured results are non-efficacy only in this race
Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Isosorbide Dinitrate / Hydralazine (BiDil)ApprovedSmall moleculeHydralazine/isosorbide dinitrate (fixed combination)Partial signal
NCT00047775: Primary composite score (all-cause mortality, first heart-failure hospitalization, quality of life) favoured isosorbide dinitrate/hydralazine vs placebo (p=0.021); the trial stopped early for a 43% reduction in all-cause mortality (p=0.012) (BiDil label, A-HeFT).
Ivabradine (Corlanor)
ApprovedUS marketing discontinued
Small moleculeIf (funny) channelReliable signal
NCT02441218: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure. (All over the study (up to 42 months).): Ivabradine 793 participants | Placebo 937 participants
Sacubitril / Valsartan (Entresto)ApprovedSmall moleculeNeprilysin + Angiotensin II receptor (dual)Partial signal
NCT01035255: Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization (up to 51 months): LCZ696 — Primary Composite: 914 participants; CV death: 558 participants; 1st HF Hospitalization: 537 participants | Enalapril — Primary Composite: 1117 participants; CV death: 693 participants; 1st HF Hospitalization: 658 participants
NCT01920711: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. (Total follow up time (up to 57 months)): LCZ696 — Primary Composite Events: 894 Events; Total Hospitalizations for heart failure: 690 Events; Cardiovascular death: 204 Events | Valsartan — Primary Composite Events: 1009 Events; Total Hospitalizations for heart failure: 797 Events; Cardiovascular death: 212 Events missed
Sotagliflozin (Inpefa)ApprovedSmall moleculeSGLT1/2 (dual)Partial signal
NCT03315143: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 30 months): Sotagliflozin 5.6 events per 100-person years | Placebo 7.5 events per 100-person years
NCT03521934: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 21.9 months): Sotagliflozin 51 events per 100-person years | Placebo 76.3 events per 100-person years
Torsemide (Soaanz)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Vericiguat (Verquvo)ApprovedSmall moleculeSoluble guanylate cyclasePartial signal
NCT02861534: CV death or first HF hospitalization, vericiguat vs placebo: 897 of 2526 (35.5%) vs 972 of 2524 (38.5%) over a median 10.8 months; HR 0.90 (95% CI 0.82 to 0.98), P = 0.02. Met.
NCT05093933: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years (Up to approximately 36 months (from randomization to the primary completion data cutoff)): Vericiguat 11.3 Pts. with event/100 patient-yrs at risk | Placebo 12.2 Pts. with event/100 patient-yrs at risk missed
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet gradedNo reviewed efficacy summary in this indication
BalcinrenonePhase 3Small moleculeMineralocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
Baxdrostat (Baxfendy)Phase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
CardiAMPPhase 3Cell therapyCardiac cell therapyPartial signal
NCT02438306: 3-tiered Finkelstein-Schoenfeld primary endpoint at 12 months (interim, 102 of eventual 125 patients): Tier 1 all-cause death 5.6% CardiAMP vs 5.3% control (P=.42); Tier 2 MACCE 16.7% vs 15.8% (P=.82); Tier 3 6MWT change +36.1m vs +33.4m (P=.6) - none reached significance; DSMB futility review concluded the trial was unlikely to meet its primary endpoint missed
CoramitugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
ElecoglipronPhase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Ferric Derisomaltose (Monoferric / Monofer)Phase 3Iron Complex (iv)Iron repletionWeak signal
NCT00537186: Single-arm, open-label safety study with no comparator and no formal efficacy test. All registered primary outcomes are safety measures (adverse events, serious adverse events, physical examination, vital signs, laboratory tests). A published pilot study that appears to be this trial (Hildebrandt et al. 2010, n=20) reported no treatment-related adverse reactions and no clinically significant changes in laboratory safety tests or vital signs over 8 weeks.
HiCM-188 (allogeneic iPSC-Cardiomyocytes)Phase 3Cell therapyCardiac cell therapyPartial signalNo reviewed efficacy summary in this indication
Levosimendan (Simdax)Phase 3Small moleculeCardiac troponin C (calcium sensitizer)Partial signal
NCT00348504: All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P = .40). missed
NCT00048425: REVIVE II, n=600: 5-day clinical-course composite primary endpoint improved 33% more often and worsened 26% less often with levosimendan vs placebo (p=0.015).
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
Omecamtiv MecarbilPhase 3Small moleculeCardiac myosin (activator)Reliable signal
NCT02929329: Time to Cardiovascular Death or First Heart Failure Event (From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.): Omecamtiv Mecarbil 37% vs Placebo 39.1%
NCT03759392: Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20 (Baseline and Week 20): Omecamtiv Mecarbil -0.239 mL/min/kg (Standard Error 0.1718) vs Placebo 0.207 mL/min/kg (Standard Error 0.2412) missed
OPC-61815 (Samtasu)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT03772041: Change From Baseline in Body Weight (Baseline, Day 6): OPC-61815 Injection 16 mg -1.67 kg (95% CI -1.93 to -1.41) vs Tolvaptan Tablet 15mg -1.36 kg (95% CI -1.62 to -1.1)
QiShenYiQiPhase 3BotanicalTraditional Chinese medicine (multi-component)Partial signalNo reviewed efficacy summary in this indication
Recombinant Human Neuregulin-1 (rhNRG-1) (Neucardin)Phase 3Protein / enzyme therapeuticErbB2/ErbB4 (neuregulin pathway)Partial signalNo reviewed efficacy summary in this indication
Rexlemestrocel-LPhase 3Cell therapyMesenchymal precursor cells (MPCs)Weak signalFeatured results are safety only in this race
Sotatercept (Winrevair)Phase 3Protein / enzyme therapeuticActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
Tolvaptan (Samsca)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT00071331: All-cause mortality: tolvaptan 25.9% vs placebo 26.3% (HR 0.98, 95% CI 0.87-1.11, P=.68). Composite of CV death or HF hospitalization: tolvaptan 42.0% vs placebo 40.2% (HR 1.04, 95% CI 0.95-1.14, P=.55). missed
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
DanicamtivPhase 2/3Small moleculeCardiac myosin (activator)Weak signal
NCT03447990: Troponin I increase: 3/12 danicamtiv vs 0/12 placebo in SAD cohorts; 7/30 danicamtiv vs 0/10 placebo in MAD cohorts.
IstaroximePhase 2/3Small moleculeNa-K ATPase / SERCA2aPartial signal
NCT02617446: Change in E/Ea Ratio (24 hours): Istaroxime 0.5 µg/kg/Min -4.55 Unitless ratio (95% CI -6.05--3.04) vs Placebo Cohort I -1.55 Unitless ratio (95% CI -3.77-0.67) vs Istaroxime 1.0 µg/kg/Min -3.16 Unitless ratio (95% CI -4.09--2.24) vs Placebo Cohort II -1.08 Unitless ratio (95% CI -2.30-0.13); p=0.029 (Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I), p=0.009 (Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II)
AC01Phase 2Small moleculeGhrelin receptorWeak signalNo reviewed efficacy summary in this indication
ADR-002KPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
Bucindolol (Gencaro)Phase 2Small moleculeBeta-1/beta-2 adrenergic receptor (genotype-guided)Partial signal
NCT01970501: Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of Stable Sinus Rhythm (SR) on Study Drug [End of Treatment Week 24]. (end of treatment week 24): Bucindolol Hydrochloride 35.9 days (IQR 9 to 53) vs Metoprolol Succinate 33.2 days (IQR 6 to 47) missed
CDR132LPhase 2RNA / oligonucleotidemicroRNA-132Weak signalFeatured results are safety only in this race
Corteria COR-1167Phase 2PeptideCorticotropin-releasing factor receptor 2not yet gradedNo reviewed efficacy summary in this indication
DelocamtenPhase 2Small moleculeCardiac myosin (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
DeramiocelPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HRS-9057Phase 2Small moleculeVasopressin V1a/V2 receptor (dual)Weak signalNo reviewed efficacy summary in this indication
HU6Phase 2Small moleculeMitochondrial uncouplingPartial signal
NCT05284617: Weight change at 3 months (450 mg HU6 dose): -6.8 lb from baseline (p<0.0001); -6.3 lb vs placebo (p=0.003)
Jia Shen TabletPhase 2BotanicalMulti-target (ginsenoside)Weak signalNo reviewed efficacy summary in this indication
JK07Phase 2Biologic (subtype unspecified)HER3 × ErbB4Weak signalFeatured results are safety only in this race
JTT-861Phase 2Small moleculePyruvate dehydrogenasePartial signalNo reviewed efficacy summary in this indication
Mavacamten (Camzyos)Phase 2Small moleculeCardiac myosin (inhibitor)Weak signalFeatured results are safety only in this race
Ninerafaxstat (IMB-101)Phase 2Small moleculeCardiac fatty-acid oxidationWeak signal
NCT04826159: Primary, resting cardiac PCr/ATP change from baseline (single arm, no comparator): Part 1 (type 2 diabetes and obesity) +0.39 (95% CI 0.16 to 0.62; P=0.002); Part 2 (with HFpEF) +0.15 (95% CI 0.03 to 0.26; P=0.02). Dobutamine-stress PCr/ATP (Part 1) is not reported in the abstract.
PexerelgonPhase 2Small moleculeRelaxin receptor (RXFP1) / relaxinPartial signalNo reviewed efficacy summary in this indication
PF-07328948Phase 2Small moleculeBranched-chain ketoacid dehydrogenase kinase (BDK)not yet gradedNo reviewed efficacy summary in this indication
R2R01Phase 2PeptideRelaxin receptor (RXFP1) / relaxinWeak signalNo reviewed efficacy summary in this indication
RibupatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Safiglipron (HRS-7535)Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
TovinontrinePhase 2Small moleculePDE9Partial signalNo reviewed efficacy summary in this indication
Umiposgene Parvec (AB-1002)Phase 2Gene therapy / editingProtein inhibitor-1 (gene therapy)Weak signal
NCT04179643: Phase 1 first-in-human trial of a single antegrade coronary infusion of AB-1002 in NYHA III non-ischemic heart failure: no adverse events or serious adverse events were attributed by the investigators to the study treatment. Mean left ventricular ejection fraction rose from 30.5% at baseline to 42.2% at 12 months in cohort 1 and from 24.5% to 36.7% in cohort 2, and all patients with baseline and 12-month assessments had an improvement in ejection fraction of at least 5%.
XTR003Phase 2Diagnostic (pet Tracer)Myocardial fatty-acid metabolism (PET imaging)not yet gradedNo reviewed efficacy summary in this indication
AAV1.SERCA2aPhase 1/2Gene therapy / editingSERCA2a (gene therapy)not yet gradedNo reviewed efficacy summary in this indication
HS-001Phase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
HucMSC Intramyocardial TherapyPhase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
PolyCorePhase 1/2SolutionPeritoneal ultrafiltrationnot yet gradedNo reviewed efficacy summary in this indication
Anhui HygeianCells EE001Phase 1Biologic (subtype unspecified)Cardiac cell therapyWeak signalNo reviewed efficacy summary in this indication
HJB647Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 61 furthest-along competitors are listed; 13 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Extraneal (Icodextrin (peritoneal ultrafiltration)) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
Phase 4Peritoneal DialysisRecruiting
Est. primary completion 2027-04-28 · NCT05721404 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Early phase / not applicableChildren on Chronic Peritoneal DialysisNot yet recruiting
Est. primary completion 2028-06-30 · NCT07168343 · CT.gov ↗
What to watch

See the full readout calendar ↗